Drugs / Kanglaite
Kanglaite
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT03101514 | Jan 2017 → Feb 2021 | head and neck cancer | First Affiliated Hospital of Harbin Medical University | Completed | No outcome recorded |
| Phase 2 | NCT01483586 | Nov 2011 → Dec 2013 | prostate cancer | KangLaiTe USA | Terminated | No outcome recorded |
| Phase 2 | NCT00733850 | Aug 2008 → Jun 2014 | malignant pancreatic neoplasm | KangLaiTe USA | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02553187 | Sep 2015 → Jul 2017 | — | Zhejiang Kanglaite Pharmaceutical Co.Ltd | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kanglaite | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01483586 ↗ |
| Known as | KLTc | “investigational Kanglaite gelcap (KLTc)” NCT01483586 ↗ |
| Known as | KLTi | “A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer.” PMID 28819385 ↗ Jul 2017 |
| Modality | Traditional medicine (herbal / TCM) | “The research drug, KLT, is purified from a traditional Chinese medicine called coix seed.” NCT00733850 ↗ |
| Route | Intravenous | “Intravenous repeating dose” NCT00733850 ↗ |